lymphoma

The road to developing monoclonal antibodies for effectively targeting cancer was paved with tenacity, passion, and strokes of luck.

A study reveals a connection between the loss of enzymes responsible for removing methyl groups from DNA, nucleic acid knots, and cancer development in mice.

Moderna’s, Pfizer’s, and Johnson & Johnson’s shots all offered protection against the virus regardless of cancer type, although slightly less so in people with blood cancer.

A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.

The liquid biopsy, which detects cell-free tumor DNA, spotted undiagnosed cancers in some women, but had a greater number of false positives and false negatives.

About a quarter of lymphoma patients eligible for the cancer treatments are opting for experimental—and free—options instead.

In determining that the illnesses came about from exposure to glyphosate in Roundup, a California jury delivers the biggest loss so far to the herbicide manufacturer in lawsuits about the product.

An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.

Sequencing of a single gene can spot patients with a dangerous form of mycosis fungoides better than other prognostic tests.  

The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas.